TransThera | 药捷安康 is a clinical-stage biopharmaceutical company founded in 2016, aiming to address unmet medical needs by developing innovative therapeutics through an internal research platform and open innovation. Their diverse portfolio encompasses oncology, cardiovascular, and inflammatory diseases, demonstrating a commitment to transforming therapy and innovating for global patients. Having recently secured a significant CNY260.00M in Series D investment on 20 February 2023, TransThera attracted backing from prominent investors such as Trinity Innovation Fund and Honest Capital. With a focus on biotechnology and life sciences, TransThera is poised to make a substantial impact on the healthcare industry.
TransThera | 药捷安康
Transformative Therapy! Innovation for global patients.
Founded 2016
19 employees
Series D
Total: $370.00M
Biotechnology, Life Sciences
General Information
Get notified when TransThera | 药捷安康 moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track TransThera | 药捷安康
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
Biotechnology
About TransThera | 药捷安康
Taxonomy: biopharmaceutical, innovation, therapeutics, oncology, cardiovascular, inflammatory diseases, clinical-stage, research platform, open innovation, global patients, unmet medical needs, transformative therapy
Funding Rounds & Investors (3)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Series D | •••••• | 2 |
|
20 Feb 2023 |
| Series D | •••••• | 7 |
|
25 Jul 2021 |
| Series A | •••••• | 1 |
|
13 Oct 2016 |
TransThera | 药捷安康 Alternatives & Competitors
TransThera | 药捷安康 vs
Nevrargenics Ltd.
United Kingdom
Developing novel medicines for ALS, FTD, Parkinson’s, Alzheimer’s and other neurodegenerative diseas...
6 employees
TransThera | 药捷安康 vs
TransThera | 药捷安康 vs
Neuroparticle Corporation
United States
Next Generation Platform Technology for Non-invasive Brain Cancer & Neurological Therapy
1 employees
Health Care, Medical Devices
FAQ About TransThera | 药捷安康
Transformative Therapy! Innovation for global patients.
TransThera | 药捷安康 was founded in 2016.
TransThera | 药捷安康 operates in the following industries: Biotechnology, Life Sciences.
TransThera | 药捷安康 has approximately 19 employees.
TransThera | 药捷安康 has completed 3 funding rounds, raising a total of $370.00M. The latest funding stage is Series D.
Top alternatives and competitors to TransThera | 药捷安康 include Nevrargenics Ltd., Zalgen, Neuroparticle Corporation , Gene Cradle, Peptinnovate Ltd. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
TransThera | 药捷安康 and Nevrargenics Ltd. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.
Don't just browse. Track.
Signal Tracker monitors TransThera | 药捷安康 and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.